Loading...
Indications: This is the first new drug approved by the FDA for treatment of tuberculosis (TB) in the U.S. in over 25 years. Rifapentine can be used with isoniazid (INH) as a once-weekly regimen in the continuation phase of TB treatment (weeks 9 to 26) for HIV-negative persons with active TB. This regimen reduces the number of doses by 50%, greatly facilitating directly observed therapy. Although rifapentine can be used in place of rifampin in the induction phase (weeks 1 to 8) of TB treatment as well, its use in the induction phase does not result in a reduction of total doses of anti-TB therapy. Because cross-resistance between rifampin and rifapentine is nearly universal, rifapentine is not useful in treating rifampin-resistant TB. Rifap…